Protocol Ledger

NCT05696613 · Phase III · RECRUITING

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

Interventional Phase III clinical trial protocol NCT05696613 sponsored by Cerium Pharmaceuticals in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-03-13 Enrollment: 148 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05696613
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)148 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05696613
Protocol FieldVerified Registry Value
NCT IdentifierNCT05696613
Consolidated Lead SponsorCerium Pharmaceuticals
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment148 participants (ESTIMATED)
Registered Start Date2023-03-13
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI